^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

firicabtagene autoleucel (CRG-022)

i
Other names: CRG-022, CD22-CAR T-cell therapy, firi-cel
Associations
Company:
Adaptive Biotech, CARGO Therap, Stanford University
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
16d
Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL (ASH 2024)
Myeloablative conditioning with cyclophosphamide and total body irradiation precede infusion of investigational Orca-T, which consists of infusions of HSPCs and Tregs on Day 0 and an infusion of T conventional (Tcon) cells on Day 2. Here, we report very promising initial feasibility, safety and efficacy of the combination of allogeneic CD19/CD22-CAR T cells with Orca-T in patients with high-risk B-ALL. This paradigm shifting combination of allogeneic CAR T and allo-HCT resulted in 100% MRD- CR with full donor chimerism but without GVHD or severe CAR-mediated toxicity. These data, which demonstrate antigen-specific anti-tumor benefit of allogeneic CAR T cells in combination with GVHD prophylaxis mediated by Tregs and tacrolimus, have potential implications that could benefit patients with other hematologic diseases.
CAR T-Cell Therapy • IO biomarker
|
TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)
|
TP53 mutation
|
clonoSEQ
|
cyclophosphamide • Orca-T • firicabtagene autoleucel (CRG-022)
6ms
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies (clinicaltrials.gov)
P1, N=20, Recruiting, Stanford University | Not yet recruiting --> Recruiting
Enrollment open
|
CD22 (CD22 Molecule)
|
Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)
7ms
New P1 trial • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)
8ms
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. (PubMed, Leukemia)
Duration of response was overall limited (median 77 days), and CD22 expression was downregulated in 4/12 (33%) available samples at relapse. In summary, we demonstrate that closed-loop manufacturing of CD22-CAR T cells is feasible and is associated with a favorable safety profile and high CR rates in pediatric and adult r/r B-ALL, a cohort with limited CD22-CAR reporting.
P1 data • Journal • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 expression
|
firicabtagene autoleucel (CRG-022)
9ms
IRB-50836: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Active, not recruiting, Stanford University | Trial completion date: Dec 2024 --> Dec 2037
Trial completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression • CD20 negative
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
9ms
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Stanford University | Suspended --> Active, not recruiting | N=52 --> 10 | Trial completion date: Aug 2035 --> Sep 2036 | Trial primary completion date: Aug 2025 --> Oct 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
11ms
IRB-50836: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=92 --> 52 | Trial completion date: Sep 2034 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression • CD20 negative
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
11ms
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
12ms
CD22 CAR T-Cells Manufactured in Prodigy System and in Bag Culture Yield Equivalent Responses for B-ALL (TCT-ASTCT-CIBMTR 2024)
Conclusion While different expansion patterns were observed, CD22 CAR T-cells manufactured in the Prodigy were as safe and effective as those made by bag culture. As commercial CAR T-cells move to automated manufacture, CAR T-cell phenotype, expansion, and functionality especially in patients with EMD may require further study.
CAR T-Cell Therapy
|
CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule) • CRP (C-reactive protein)
|
firicabtagene autoleucel (CRG-022)
1year
A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=123, Recruiting, CARGO Therapeutics | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
1year
CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature (ASH 2023)
Patients most commonly received high-dose glucocorticoids, tocilizumab and anakinra. Additional agents for grade 4 IEC-HS included anti-thymoglobulin, dasatanib and emapalumab...The observed IFN-γ cytokine signature is consistent with myeloid cell activation and Th1 T-cell skewing that likely contributes to IEC-HS pathogenesis. These cytokines may be amenable to therapeutic intervention and further study of approaches targeting JAK/STAT and IFN-γ are warranted.
CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD22 (CD22 Molecule) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • FASLG (Fas ligand) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta)
|
Actemra IV (tocilizumab) • Kineret (anakinra) • firicabtagene autoleucel (CRG-022)
over1year
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. (PubMed, J Immunother Cancer)
With rising incidence of CD19 negative relapse, CD22 CAR T-cells are increasingly important for the treatment of B-cell malignancies. In characterizing hematologic toxicities on CD22 CAR T-cells, we demonstrate that despite endothelial activation, coagulopathy, and cytopenias, neurotoxicity was relatively mild and that CD22 and CD19 expression in the CNS differed, providing one potential hypothesis for divergent neurotoxicity profiles. Systematic characterization of on-target off-tumor toxicities of novel CAR T-cell constructs will be vital as new antigens are targeted.
Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • VCAM1 (Vascular Cell Adhesion Molecule 1)
|
CD19 expression • CD22 expression
|
anti-CD22 CAR T • firicabtagene autoleucel (CRG-022)
over1year
CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY. (EHA 2023)
After lymphodepletion (LD) with fludarabine 30 mg/m2 and cyclophosphamide 500 mg/m2 for 3 days from Day -5 to -3, patients were infused with cryopreserved CAR T-cells after a 7- to 12-day closed manufacturing process utilizing the CliniMACS Prodigy device (Miltenyi). CAR22 is a highly effective and safe salvage therapy for patients with CAR19-refractory LBCL. A multicenter phase 2 clinical trial is planned to open in 2023. CAR-T, Cellular therapy, DLBCL
Clinical • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 expression
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
over1year
IRB-50836: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov)
P1, N=92, Recruiting, Stanford University | Trial primary completion date: Sep 2022 --> Apr 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression • CD20 negative
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
almost2years
CD22 CAR T Cell Therapy Induces Durable Remissions in Patients with Large B Cell Lymphoma Who Relapse after CD19 CAR T Cell Therapy (TCT-ASTCT-CIBMTR 2023)
After lymphodepletion (LD) with fludarabine and cyclophosphamide, patients were infused with cryopreserved CAR T-cells after a 7- to 12-day closed manufacturing process utilizing the CliniMACS Prodigy device (Miltenyi). CAR22 is a highly effective and safe salvage therapy for CAR19-refractory LBCL and recently granted FDA-Breakthrough Designation. A multicenter phase 2 clinical trial is planned to open in 2023.
Clinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
2years
CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study (ASH 2022)
The CAR was manufactured using an automated CliniMACS Prodigy (Miltenyi Biotec, Bergisch Gladbach, Germany) lentiviral transduction system2 that has been previously used to successfully create single and dual-targeted CARs.3,4 Sixteen patients received lymphodepletion with fludarabine (30 mg/m2/day IV on Days -5, -4, and -3) and cyclophosphamide (500mg/m2/day on Days -5, -4, and -3) followed by fresh or cryopreserved CAR T cell infusion after a 7-9 day production time...Four patients (22%) had also received inotuzumab... The results of our Phase Ib trial recapitulate previous findings with CD22 CARs and demonstrate that this CAR maintains its safety and feasibility profile in adults and children with heavily pre-treated ALL. The CD22 CAR resulted in high rates of CR and MRD-negativity independent of prior CD19 CAR and/or blinatumomab exposure. CRS was common but reversible, and the incidence and grades of CRS, ICANS and car-HLH were consistent with long-term follow up data from CD22 CAR studies in pediatric populations.6 CD22 CARs thus present a promising option for both pediatric and adult patients with r/r ALL.
Clinical • P1 data • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • fludarabine IV • firicabtagene autoleucel (CRG-022)
2years
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Suspended, Stanford University | Enrolling by invitation --> Suspended
Trial suspension • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
over2years
New P1 trial
|
CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • CRLF2 (Cytokine Receptor Like Factor 2) • CD22 (CD22 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement
|
Orca-T • firicabtagene autoleucel (CRG-022)
over2years
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Enrolling by invitation, Stanford University | Recruiting --> Enrolling by invitation
Enrollment status • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
3years
CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy (ASH 2021)
After lymphodepletion (LD) with fludarabine and cyclophosphamide, patients are infused with cryopreserved CAR T-cells after a 7- to 11-day closed manufacturing process utilizing the CliniMACS Prodigy device (Miltenyi). Infusion of CAR22 in R/R LBCL is safe and well tolerated at DL1. Manufacturing of CAR22 was uniformly successful. With a mean follow-up of 7.3 months, the ORR and CR rates are 18/21 (86%) and 14/21 (67%), respectively.
Clinical • CAR T-Cell Therapy • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
MYC rearrangement
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)